ANI Capital Surpluse from 2010 to 2025

ANIP Stock  USD 58.92  0.27  0.46%   
ANI Pharmaceuticals Capital Surpluse yearly trend continues to be relatively stable with very little volatility. Capital Surpluse is likely to drop to about 237.5 M. During the period from 2010 to 2025, ANI Pharmaceuticals Capital Surpluse destribution of quarterly values had range of 375 M from its regression line and mean deviation of  99,187,953. View All Fundamentals
 
Capital Surpluse  
First Reported
2013-06-30
Previous Quarter
408.4 M
Current Value
495.5 M
Quarterly Volatility
97.2 M
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of ANI Pharmaceuticals over the last few years. It is ANI Pharmaceuticals' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
186.200.214.387.403.464.237.7%7%81%4%15%-49%100%
       Timeline  

ANI Capital Surpluse Regression Statistics

Arithmetic Mean220,817,875
Geometric Mean190,135,229
Coefficient Of Variation56.82
Mean Deviation99,187,953
Median186,812,000
Standard Deviation125,479,624
Sample Variance15745.1T
Range375M
R-Value0.85
Mean Square Error4538.7T
R-Squared0.73
Significance0.000024
Slope22,533,335
Total Sum of Squares236177T

ANI Capital Surpluse History

2025237.5 M
2024464.5 M
2022403.9 M
2021387.8 M
2020214.4 M
2019200.8 M
2018186.8 M

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse464.5 M237.5 M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…